

Raltegravir Pediatric Formulation

Version 3.1 Revision Date: 26.09.2023 SDS Number: 20385-00026 Date of last issue: 20.03.2023
 Date of first issue: 09.10.2014

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Raltegravir Pediatric Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-stance/Mixture : Pharmaceutical

Recommended restrictions on use : Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD
 117 16th Road
 1685 Halfway house, Midrand, South Africa

Telephone : +27 11 655 3000

E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Serious eye damage, Category 1	H318: Causes serious eye damage.
Reproductive toxicity, Category 2	H361d: Suspected of damaging the unborn child.
Specific target organ toxicity - single exposure, Category 3	H335: May cause respiratory irritation.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms : 

Signal word : Danger

Hazard statements : H318 Causes serious eye damage.
 H335 May cause respiratory irritation.
 H361d Suspected of damaging the unborn child.

Raltegravir Pediatric Formulation

Version 3.1 Revision Date: 26.09.2023 SDS Number: 20385-00026 Date of last issue: 20.03.2023
 Date of first issue: 09.10.2014

Precautionary statements : **Prevention:**
 P201 Obtain special instructions before use.
 P261 Avoid breathing dust.
 P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
 P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.
 P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor.
 P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Hazardous components which must be listed on the label:

Raltegravir

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Raltegravir	871038-72-1	Eye Dam. 1; H318 Repr. 2; H361d STOT SE 3; H335	>= 20 - < 30

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
 When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment

Raltegravir Pediatric Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
3.1	26.09.2023	20385-00026	Date of first issue: 09.10.2014

- when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention immediately.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

- Risks : Causes serious eye damage.
May cause respiratory irritation.
Suspected of damaging the unborn child.
- Contact with dust can cause mechanical irritation or drying of the skin.

4.3 Indication of any immediate medical attention and special treatment needed

- Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

- Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)

Raltegravir Pediatric Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
3.1	26.09.2023	20385-00026	Date of first issue: 09.10.2014

Fluorine compounds
Chlorine compounds
Sulphur oxides
Metal oxides

5.3 Advice for firefighters

- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
-

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

- Personal precautions : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

- Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

- Methods for cleaning up : Surround spill with absorbents and place a damp covering over the area to minimise entry of the material into the air. Add excess liquid to allow the material to enter into solution. Soak up with inert absorbent material. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

Raltegravir Pediatric Formulation

Version 3.1 Revision Date: 26.09.2023 SDS Number: 20385-00026 Date of last issue: 20.03.2023
 Date of first issue: 09.10.2014

SECTION 7: Handling and storage

7.1 Precautions for safe handling

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
 Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Avoid breathing dust.
 Do not swallow.
 Do not get in eyes.
 Avoid prolonged or repeated contact with skin.
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
 Keep container tightly closed.
 Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.
 Minimize dust generation and accumulation.
 Keep container closed when not in use.
 Keep away from heat and sources of ignition.
 Take precautionary measures against static discharges.
 Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

7.2 Conditions for safe storage, including any incompatibilities

- Requirements for storage areas and containers : Keep in properly labelled containers. Store locked up. Keep tightly closed. Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations.
- Advice on common storage : Do not store with the following product types:
 Strong oxidizing agents

7.3 Specific end use(s)

- Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Raltegravir	871038-72-1	TWA	1000 µg/m ³ (OEB 1)	Internal

Raltegravir Pediatric Formulation

Version 3.1 Revision Date: 26.09.2023 SDS Number: 20385-00026 Date of last issue: 20.03.2023
 Date of first issue: 09.10.2014

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health effects	Value
1,2-Benzisothiazol-3(2H)-one 1,1-dioxide, sodium salt	Workers	Inhalation	Long-term systemic effects	1,68 mg/m ³
	Workers	Skin contact	Long-term systemic effects	0,952 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	0,414 mg/m ³
	Consumers	Skin contact	Long-term systemic effects	0,476 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
1,2-Benzisothiazol-3(2H)-one 1,1-dioxide, sodium salt	Fresh water	0,0158 mg/l
	Marine water	0,00158 mg/l
	Intermittent use/release	0,158 mg/l

8.2 Exposure controls

Engineering measures

Minimize workplace exposure concentrations.
 Apply measures to prevent dust explosions.
 Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).
 If sufficient ventilation is unavailable, use with local exhaust ventilation.

Personal protective equipment

Eye/face protection : Wear the following personal protective equipment:
 Chemical resistant goggles must be worn.
 If splashes are likely to occur, wear:
 Face-shield

Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Skin and body protection : Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.
 Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

Raltegravir Pediatric Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
3.1	26.09.2023	20385-00026	Date of first issue: 09.10.2014

Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance	:	powder
Colour	:	yellow-orange
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

9.2 Other information

Raltegravir Pediatric Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
3.1	26.09.2023	20385-00026	Date of first issue: 09.10.2014

Flammability (liquids)	:	No data available
Molecular weight	:	No data available
Particle size	:	No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
---------------------	---	--

10.4 Conditions to avoid

Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
---------------------	---	---

10.5 Incompatible materials

Materials to avoid	:	Oxidizing agents
--------------------	---	------------------

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
--	---	--

Acute toxicity

Not classified based on available information.

Components:

Raltegravir:

Acute oral toxicity	:	LD50 (Mouse, male and female): > 2.000 mg/kg
---------------------	---	--

Skin corrosion/irritation

Not classified based on available information.

Components:

Raltegravir:

Raltegravir Pediatric Formulation

Version 3.1 Revision Date: 26.09.2023 SDS Number: 20385-00026 Date of last issue: 20.03.2023
Date of first issue: 09.10.2014

Species : Rabbit
Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye damage.

Components:**Raltegravir:**

Species : Bovine cornea
Result : Severe irritation

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Raltegravir:**

Test Type : Local lymph node assay (LLNA)
Species : Mouse
Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:**Raltegravir:**

Genotoxicity in vitro : Test Type: reverse mutation assay
Result: negative

Test Type: Alkaline elution assay
Test system: rat hepatocytes
Result: negative

Test Type: Chromosomal aberration
Method: OECD Test Guideline 473
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test
Species: Mouse
Result: negative

Test Type: Chromosomal aberration
Method: OECD Test Guideline 475
Result: negative

Carcinogenicity

Not classified based on available information.

Raltegravir Pediatric Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
3.1	26.09.2023	20385-00026	Date of first issue: 09.10.2014

Components:

Raltegravir:

Species : Mouse, male and female
 Exposure time : 104 weeks
 Result : negative

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Raltegravir:

Effects on fertility : Test Type: Fertility/early embryonic development
 Species: Rat, male and female
 Application Route: Oral
 General Toxicity - Parent: NOAEL: 600 mg/kg body weight
 Result: negative

Effects on foetal development : Species: Rat
 Application Route: Oral
 General Toxicity Maternal: NOAEL: \geq 600 mg/kg body weight
 Teratogenicity: LOAEL F1: 300 mg/kg body weight
 Symptoms: Skeletal malformations
 Result: positive

Species: Rabbit
 General Toxicity Maternal: NOAEL: \geq 1.000 mg/kg body weight
 Teratogenicity: NOAEL: \geq 1.000 mg/kg body weight
 Result: negative

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

STOT - single exposure

May cause respiratory irritation.

Components:

Raltegravir:

Exposure routes : Inhalation
 Target Organs : Respiratory Tract
 Assessment : May cause respiratory irritation.

STOT - repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

Raltegravir:

Species : Dog

Raltegravir Pediatric Formulation

Version 3.1 Revision Date: 26.09.2023 SDS Number: 20385-00026 Date of last issue: 20.03.2023
 Date of first issue: 09.10.2014

NOAEL : 90 mg/kg
 Application Route : Oral
 Exposure time : 371 d
 Symptoms : Vomiting

Species : Rat
 NOAEL : 30 mg/kg
 LOAEL : 120 mg/kg
 Application Route : Oral
 Exposure time : 189 d
 Target Organs : Stomach

Species : Mouse
 NOAEL : 50 mg/kg
 LOAEL : 500 mg/kg
 Application Route : Oral
 Exposure time : 14 Weeks
 Target Organs : Stomach

Species : Rat
 NOAEL : 50 mg/kg
 LOAEL : 200 mg/kg
 Application Route : Oral
 Exposure time : 8 Weeks
 Target Organs : Stomach

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Raltegravir:

Ingestion : Symptoms: Nausea, Diarrhoea, Headache, Fever, Rash, Skin irritation

SECTION 12: Ecological information

12.1 Toxicity

Components:

Raltegravir:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l
 Exposure time: 96 h
 Method: OECD Test Guideline 203

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 100 mg/l
 Exposure time: 96 h
 Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
 Exposure time: 48 h

Raltegravir Pediatric Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
3.1	26.09.2023	20385-00026	Date of first issue: 09.10.2014

Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 66 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 3,8 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50 : > 1.000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC : 1.000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity) : NOEC: 9,3 mg/l
Exposure time: 33 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 9,5 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211

12.2 Persistence and degradability

Components:

Raltegravir:

Biodegradability : Result: rapidly degradable
Biodegradation: 50 %
Exposure time: 9 d
Method: OECD Test Guideline 302B

Stability in water : Hydrolysis: < 10 %(5 d)
Method: OECD Test Guideline 111

12.3 Bioaccumulative potential

Components:

Raltegravir:

Partition coefficient: n-octanol/water : log Pow: -0,328

12.4 Mobility in soil

No data available

Raltegravir Pediatric Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
3.1	26.09.2023	20385-00026	Date of first issue: 09.10.2014

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects

Product:

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA : Not regulated as a dangerous good

14.2 UN proper shipping name

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA : Not regulated as a dangerous good

14.3 Transport hazard class(es)

Raltegravir Pediatric Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
3.1	26.09.2023	20385-00026	Date of first issue: 09.10.2014

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA	:	Not regulated as a dangerous good

14.4 Packing group

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA (Cargo)	:	Not regulated as a dangerous good
IATA (Passenger)	:	Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information**15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture**

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H318 : Causes serious eye damage.

H335 : May cause respiratory irritation.

Raltegravir Pediatric Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
3.1	26.09.2023	20385-00026	Date of first issue: 09.10.2014

H361d : Suspected of damaging the unborn child.

Full text of other abbreviations

Eye Dam. : Serious eye damage
 Repr. : Reproductive toxicity
 STOT SE : Specific target organ toxicity - single exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Eye Dam. 1	H318
Repr. 2	H361d
STOT SE 3	H335

Classification procedure:

Calculation method
Calculation method
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for

Raltegravir Pediatric Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 20.03.2023
3.1	26.09.2023	20385-00026	Date of first issue: 09.10.2014

safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN